KXS Balances the Tryptophan Metabolism in Mild to Moderate Depressed Patients and Chronic Restraint Stress Induced Depressive Rats

References

• World Health O. Depression and other common mental disorders: global health estimates; 2017. Available from: https://apps.who.int/iris/handle/10665/254610. Accessed October 11, 2022.
   Google Scholar
• Baldessarini R, Forte A, Selle V, et al. Morbidity in depressive disorders. Psychother Psychosom. 2017;86(2):65–72. doi:10.1159/000448661
   PubMed Web of Science ®Google Scholar
• Ménard C, Hodes GE, Russo SJ. Pathogenesis of depression: insights from human and rodent studies. Neuroscience. 2016;321:138–162. doi:10.1016/j.neuroscience.2015.05.053
   PubMed Web of Science ®Google Scholar
• Delgado PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry. 2000;61(Suppl 6):7–11.
   PubMed Web of Science ®Google Scholar
• Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. J Neuropsychiatry Clin Neurosci. 1995;7(4):524–533. doi:10.1176/jnp.7.4.524
   Web of Science ®Google Scholar
• van Praag HM, Korf J. A pilot study of some kinetic aspects of the metabolism of 5-hydroxytryptamine in depressive patients. Biol Psychiatry. 1971;3(2):105–112.
   Web of Science ®Google Scholar
• Berlim M, Turecki G. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur neuropsychopharmacol. 2007;17(11):696–707. doi:10.1016/j.euroneuro.2007.03.009
   PubMed Web of Science ®Google Scholar
• Wigner P, Czarny P, Galecki P, Su KP, Sliwinski T. The molecular aspects of oxidative & nitrosative stress and the tryptophan catabolites pathway (TRYCATs) as potential causes of depression. Psychiatry Res. 2018;262:566–574. doi:10.1016/j.psychres.2017.09.045
   PubMed Web of Science ®Google Scholar
• Shaw K, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev. 2001;(3):Cd003198. doi:10.1002/14651858.Cd003198
   Google Scholar
• Réus GZ, Jansen K, Titus S, Carvalho AF, Gabbay V, Quevedo J. Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: evidences from animal and human studies. J Psychiatr Res. 2015;68:316–328. doi:10.1016/j.jpsychires.2015.05.007
   PubMed Web of Science ®Google Scholar
• Fu H, Xu Z, Zhang XL, Zheng GQ. Kaixinsan, a well-known Chinese herbal prescription, for alzheimer’s disease and depression: a preclinical systematic review. Front Neurosci. 2019;13:1421. doi:10.3389/fnins.2019.01421
   Web of Science ®Google Scholar
• Feng DD, Tang T, Lin XP, et al. Nine traditional Chinese herbal formulas for the treatment of depression: an ethnopharmacology, phytochemistry, and pharmacology review. Neuropsychiatr Dis Treat. 2016;12:2387–2402. doi:10.2147/ndt.S114560
   PubMed Web of Science ®Google Scholar
• Chen C, Hu Y, Dong X, Zhou X, Mu L, Liu P. Proteomic analysis of the antidepressant effects of shen-zhi-ling in depressed patients: identification of proteins associated with platelet activation and lipid metabolism. Cell Mol Neurobiol. 2018;38(5):1123–1135. doi:10.1007/s10571-018-0582-9
   Web of Science ®Google Scholar
• Hu Y, Wang Y, Chen C, et al. A randomized, placebo-controlled, double-blind study on the effects of SZL on patients with mild to moderate depressive disorder with comparison to fluoxetine. J Ethnopharmacol. 2021;281:114549. doi:10.1016/j.jep.2021.114549
   Web of Science ®Google Scholar
• Dong XZ, Li ZL, Zheng XL, Mu LH, Zhang GQ, Liu P. A representative prescription for emotional disease, Ding-Zhi-Xiao-Wan restores 5-HT system deficit through interfering the synthesis and transshipment in chronic mild stress-induced depressive rats. J Ethnopharmacol. 2013;150(3):1053–1061. doi:10.1016/j.jep.2013.10.018
   Web of Science ®Google Scholar
• He Y, Wang Y, Liu S, et al. A metabolomic study of the urine of rats with Alzheimer’s disease and the efficacy of Ding-Zhi-Xiao-Wan on the afflicted rats. J Sep Sci. 2020;43(8):1458–1465. doi:10.1002/jssc.201900944
   Web of Science ®Google Scholar
• Dong XZ, Wang DX, Zhang TY, Liu X, Liu P, Hu Y. Identification of protein targets for the antidepressant effects of Kai-Xin-San in Chinese medicine using isobaric tags for relative and absolute quantitation. Neural Regen Res. 2020;15(2):302–310. doi:10.4103/1673-5374.265555
   Web of Science ®Google Scholar
• Matthes S, Bader M. Peripheral serotonin synthesis as a new drug target. Trends Pharmacol Sci. 2018;39(6):560–572. doi:10.1016/j.tips.2018.03.004
   Web of Science ®Google Scholar
• Schwarcz R, Du F. Quinolinic acid and kynurenic acid in the mammalian brain. Adv Exp Med Biol. 1991;294:185–199. doi:10.1007/978-1-4684-5952-4_17
   Google Scholar
• Heyes MP. Metabolism and neuropathologic significance of quinolinic acid and kynurenic acid. Biochem Soc Trans. 1993;21(1):83–89. doi:10.1042/bst0210083
   Web of Science ®Google Scholar
• Cervenka I, Agudelo LZ, Ruas JL. Kynurenines: tryptophan’s metabolites in exercise, inflammation, and mental health. Science. 2017;357(6349). doi:10.1126/science.aaf9794
   Web of Science ®Google Scholar
• Kuwano N, Kato TA, Setoyama D, et al. Tryptophan-kynurenine and lipid related metabolites as blood biomarkers for first-episode drug-naïve patients with major depressive disorder: an exploratory pilot case-control study. J Affect Disord. 2018;231:74–82. doi:10.1016/j.jad.2018.01.014
   PubMed Web of Science ®Google Scholar
• Liu H, Ding L, Zhang H, et al. The metabolic factor kynurenic acid of kynurenine pathway predicts major depressive disorder. Front Psychiatry. 2018;9:552. doi:10.3389/fpsyt.2018.00552
   PubMed Web of Science ®Google Scholar
• Wigner P, Czarny P, Galecki P, Sliwinski T. Oxidative and nitrosative stress as well as the tryptophan catabolites pathway in depressive disorders. Psychiatr Danub. 2017;29(4):394–400. doi:10.24869/psyd.2017.394
   Web of Science ®Google Scholar
• Benatti C, Blom JM, Rigillo G, et al. Disease-induced neuroinflammation and depression. CNS Neurol Disord Drug Targets. 2016;15(4):414–433. doi:10.2174/1871527315666160321104749
   PubMed Web of Science ®Google Scholar
• Halaris A, Myint AM, Savant V, et al. Does escitalopram reduce neurotoxicity in major depression? J Psychiatr Res. 2015;66–67:118–126. doi:10.1016/j.jpsychires.2015.04.026
   PubMed Web of Science ®Google Scholar
• Hunt C, Macedo ECT, Suchting R, et al. Effect of immune activation on the kynurenine pathway and depression symptoms - A systematic review and meta-analysis. Neurosci Biobehav Rev. 2020;118:514–523. doi:10.1016/j.neubiorev.2020.08.010
   PubMed Web of Science ®Google Scholar
• Müller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry. 2007;12(11):988–1000. doi:10.1038/sj.mp.4002006
   PubMed Web of Science ®Google Scholar
• Chen Y, Guillemin GJ. Kynurenine pathway metabolites in humans: disease and healthy states. Int J Tryptophan Res. 2009;2:1–19. doi:10.4137/ijtr.s2097
   PubMed Web of Science ®Google Scholar
• Müller N, Schwarz MJ. A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. Eur Arch Psychiatry Clin Neurosci. 2008;258(Suppl 2):97–106. doi:10.1007/s00406-008-2012-3
   Web of Science ®Google Scholar
• Ogyu K, Kubo K, Noda Y, et al. Kynurenine pathway in depression: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2018;90:16–25. doi:10.1016/j.neubiorev.2018.03.023
   PubMed Web of Science ®Google Scholar
• Eskelund A, Li Y, Budac DP, et al. Drugs with antidepressant properties affect tryptophan metabolites differently in rodent models with depression-like behavior. J Neurochem. 2017;142(1):118–131. doi:10.1111/jnc.14043
   Web of Science ®Google Scholar
• Li CC, Jiang N, Gan L, et al. Peripheral and cerebral abnormalities of the tryptophan metabolism in the depression-like rats induced by chronic unpredicted mild stress. Neurochem Int. 2020;138:104771. doi:10.1016/j.neuint.2020.104771
   PubMed Web of Science ®Google Scholar
• Wang J, Li X, He S, et al. Regulation of the kynurenine metabolism pathway by Xiaoyao San and the underlying effect in the hippocampus of the depressed rat. J Ethnopharmacol. 2018;214:13–21. doi:10.1016/j.jep.2017.11.037
   PubMed Web of Science ®Google Scholar
• Dang H, Sun L, Liu X, et al. Preventive action of Kai Xin San aqueous extract on depressive-like symptoms and cognition deficit induced by chronic mild stress. Exp Biol Med. 2009;234(7):785–793. doi:10.3181/0812-rm-354
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang D, Zhou J, Mao-Xing LI, Jia ZP, Zhang RX. Mechanism and effects of kaixin powder, danggui shaoyao powder and hypericum perforatum L. on the behavior of high fat rats with chronic stress. China J Tradit Chin Med Pharm. 2016;31:4230–4235.
   Google Scholar
• Yan L, Hu Q, Mak MS, et al. A Chinese herbal decoction, reformulated from Kai-Xin-San, relieves the depression-like symptoms in stressed rats and induces neurogenesis in cultured neurons. Sci Rep. 2016;6:30014. doi:10.1038/srep30014
   PubMed Web of Science ®Google Scholar
• Zhu KY, Xu SL, Choi RC, Yan AL, Dong TT, Tsim KW. Kai-xin-san, a Chinese herbal decoction containing ginseng radix et rhizoma, polygalae radix, acori tatarinowii rhizoma, and poria, stimulates the expression and secretion of neurotrophic factors in cultured astrocytes. Evid Based Complement Alternat Med. 2013;2013:731385. doi:10.1155/2013/731385
   Web of Science ®Google Scholar
• Dong XZ, Wang DX, Lu YP, Yuan S, Liu P, Hu Y. Antidepressant effects of Kai-Xin-San in fluoxetine-resistant depression rats. Braz J Med Biol Res. 2017;50(10):e6161. doi:10.1590/1414-431x20176161
   PubMed Web of Science ®Google Scholar